{
    "2020-12-15": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint",
                "features": {
                    "keywords": [
                        "Novartis",
                        "COVID-19",
                        "Study",
                        "Fails",
                        "Primary",
                        "Endpoint"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "20 Biggest Healthcare Companies By Revenue",
                "features": {
                    "keywords": [
                        "Biggest",
                        "Healthcare",
                        "Companies",
                        "Revenue"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema",
                "features": {
                    "keywords": [
                        "Novartis",
                        "positive",
                        "topline",
                        "results",
                        "Phase",
                        "III",
                        "trial",
                        "Beovu®",
                        "diabetic",
                        "macular",
                        "edema"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}